Compare SLRX & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLRX | RVLV |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 2.1B |
| IPO Year | N/A | 2019 |
| Metric | SLRX | RVLV |
|---|---|---|
| Price | $0.84 | $31.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $26.42 |
| AVG Volume (30 Days) | 627.1K | ★ 1.1M |
| Earning Date | 11-14-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.78 |
| EPS | N/A | ★ 0.78 |
| Revenue | N/A | ★ $1,195,039,000.00 |
| Revenue This Year | N/A | $8.95 |
| Revenue Next Year | N/A | $6.42 |
| P/E Ratio | ★ N/A | $40.27 |
| Revenue Growth | N/A | ★ 9.24 |
| 52 Week Low | $0.51 | $16.80 |
| 52 Week High | $108.00 | $33.68 |
| Indicator | SLRX | RVLV |
|---|---|---|
| Relative Strength Index (RSI) | 47.46 | 68.72 |
| Support Level | $0.51 | $29.56 |
| Resistance Level | $0.68 | $31.48 |
| Average True Range (ATR) | 0.06 | 1.05 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 84.17 | 91.82 |
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.